A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
暂无分享,去创建一个
Yingdong Zhao | Holden Maecker | Sylvia Janetzki | Damien Chaussabel | George Coukos | Antoni Ribas | Francesco M Marincola | Xifeng Wu | Ena Wang | Licia Rivoltini | Senthamil Selvan | F. Marincola | A. Palucka | D. Chaussabel | Xifeng Wu | B. Seliger | G. Coukos | M. Dhodapkar | J. Kirkwood | G. Trinchieri | A. Ribas | B. Fox | L. Butterfield | C. Slingluff | H. Maecker | J. Wigginton | E. Wang | M. Maio | H. Zwierzina | Yingdong Zhao | D. Stroncek | S. Selvan | B. Zeskind | Peter P. Lee | M. Disis | L. Rivoltini | M. Thurin | G. Masucci | L. Hakansson | S. Khleif | Giorgio Trinchieri | S. Janetzki | T. Kleen | C. Maccalli | Cristina Maccalli | D. Schendel | David F Stroncek | Michele Maio | Peter P Lee | Craig L Slingluff | Barbara Seliger | Bernard A Fox | Benjamin Zeskind | John M Kirkwood | Thomas O Kleen | Heinz Zwierzina | Lisa H Butterfield | Mary L Disis | Samir N Khleif | Magdalena Thurin | Jon Wigginton | Madhav Dhodapkar | Leif Håkansson | Anatoli Malyguine | Giuseppe Masucci | A Karolina Palucka | Douglas M Potter | Dolores Schendel | Howard Streicher | Mai-Britt Zocca | A. Malyguine | D. Potter | H. Streicher | M. Zocca | Bernard A. Fox
[1] Yingdong Zhao,et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. , 2002, Cancer research.
[2] F. Marincola,et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection , 2007, Genome Biology.
[3] L. Butterfield,et al. Development of a Potency Assay for Human Dendritic Cells: IL-12p70 Production , 2008, Journal of immunotherapy.
[4] Holden T Maecker,et al. Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors , 2007, Journal of immune based therapies and vaccines.
[5] Michael E. Phelps,et al. Molecular imaging of lymphoid organs and immune activation using positron emission tomography with a new 18F-labeled 2′-deoxycytidine analog , 2008, Nature Medicine.
[6] F. Marincola,et al. Journal of Translational Medicine Molecular Signatures Induced by Interleukin-2 on Peripheral Blood Mononuclear Cells and T Cell Subsets , 2022 .
[7] Antoni Ribas,et al. PET Imaging of Cancer Immunotherapy , 2008, Journal of Nuclear Medicine.
[8] B. Comin-Anduix,et al. Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays , 2006, Clinical Cancer Research.
[9] Francesco M Marincola,et al. Effects of storage time and exogenous protease inhibitors on plasma protein levels. , 2006, American journal of clinical pathology.
[10] M. Atkins,et al. Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy , 2002, Journal of immunotherapy.
[11] F. Marincola,et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration , 2002, Genome Biology.
[12] S. Signoretti,et al. Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.
[13] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[14] E. Wang,et al. Potency analysis of cellular therapies: the emerging role of molecular assays , 2007, Journal of Translational Medicine.
[15] Virginia Pascual,et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. , 2008, Immunity.
[16] Francesco M Marincola,et al. Bottom up: a modular view of immunology. , 2008, Immunity.
[17] Holden T Maecker,et al. Maximizing the Retention of Antigen Specific Lymphocyte Function after Cryopreservation , 2001 .
[18] F. Marincola,et al. The immunologic constant of rejection. , 2008, Trends in immunology.
[19] F. Marincola,et al. A natural history of melanoma: serial gene expression analysis. , 2000, Immunology today.
[20] F. Marincola,et al. Inflammatory Protein Profile During Systemic High Dose Interleukin-2 Administration , 2005 .
[21] Yingdong Zhao,et al. Journal of Translational Medicine Transcriptional Patterns, Biomarkers and Pathways Characterizing Nasopharyngeal Carcinoma of Southern China , 2008 .
[22] R. Foà,et al. The use of microarray technologies in clinical oncology , 2006, Journal of Translational Medicine.
[23] F. Marincola,et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis , 2008, Journal of Translational Medicine.
[24] J. Weinstein,et al. Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. , 2005, Journal of immunotherapy.
[25] F. Marincola,et al. Selection and validation of endogenous reference genes using a high throughput approach , 2004, BMC Genomics.
[26] Sylvia Janetzki,et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) , 2007, Cancer Immunology, Immunotherapy.
[27] F. Marincola,et al. Melanoma-restricted genes , 2004, Journal of Translational Medicine.
[28] F. Marincola,et al. Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion , 2006, Journal of Translational Medicine.
[29] L. Hood,et al. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood , 2008, Nature Biotechnology.
[30] J. Wolchok,et al. How can we tell when cancer vaccines vaccinate? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[32] F. Marincola,et al. Gene expression profiling of cutaneous wound healing , 2007, Journal of Translational Medicine.
[33] B. Martin,et al. Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture , 2006, Journal of Translational Medicine.
[34] Callum G. Fraser,et al. Biological Variation: From Principles to Practice , 2001 .
[35] D. Ankerst,et al. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT , 2005, BMC Immunology.
[36] James R Beasley,et al. Miniaturized, ultra-high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays. , 2004, Assay and drug development technologies.
[37] Holden T Maecker,et al. Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides , 2008, BMC Immunology.
[38] Gabriel A Kwong,et al. DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins. , 2007, Journal of the American Chemical Society.
[39] Garry P Nolan,et al. Chemical labeling strategies for cell biology , 2006, Nature Methods.
[40] Yingdong Zhao,et al. Common cancer biomarkers. , 2006, Cancer research.